

Huntington Disease (HD)

## A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

**Trial Status**  
Completed

**Trial Runs In**  
17 Countries

**Trial Identifier**  
NCT03761849 GENERATION HD1  
BN40423

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03761849 GENERATION HD1 BN40423**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=25 Years & <= 65 Years

**Healthy Volunteers**  
No

---